Attention:

Certain features of Sigma-Aldrich.com will be down for maintenance the evening of Friday August 18th starting at 8:00 pm CDT until Saturday August 19th at 12:01 pm CDT.   Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

Antipsychotics

In 2011, 54 million prescriptions were filled for antipsychotics representing a 2.4% increase over the previous year according to the market research firm IMS Health.1 Antipsychotics are a class of drugs prescribed for treatment of serious psychiatric disorders such as schizophrenia, bipolar disorder, and major depression disorder. Antipsychotics are separated into two classes - older first generation drugs known as typicals and newer second generation drugs called atypicals. Both typical and atypical antipsychotics have serious adverse effects associated with their use including rapid weight gain, diabetes, cardiovascular disease, and movement impairment. Since many antipsychotics, especially the older typicals, have a narrow therapeutic window, therapeutic drug monitoring (TDM) is required to ensure patients remain within the drug’s optimal dosing range.

Sigma-Aldrich's Cerilliant brand offers the widest selection of Certified Spiking Solutions® for antipsychotics as well as their metabolites and stable-labeled internal standards. Our product listing includes older typical antipsychotics such as haloperidol, fluphenazine, thioridazine, and chlorpromazine as well as newer atypical antipsychotics from aripiprazole, clozapine, iloperidone, and olanzapine to paliperidone, lurasidone, quetiapine, risperidone and ziprasidone.

Cerilliant reference standards are manufactured and certified to the highest industry standards including ISO Guide 34, ISO/IEC 17025, and ISO 13485. Each Certified Spiking Solution® is supported by a comprehensive Certificate of Analysis (COA) that provides all analytical data and uncertainty and traceability information to support regulatory requirements.

Materials

     

References

  1. http://www.imshealth.com/ims/Global/Content/Corporate/Press%20Room/IMS%20in%20the%20News/Documents/PM360_IMS_Antipsychotics_0112.pdf

 

Related Links